Literature DB >> 31876203

New developments in the field of mastocytosis and mast cell activation syndromes: a summary of the Annual Meeting of the European Competence Network on Mastocytosis (ECNM) 2019.

Michel Arock1,2, Karl Sotlar3, Jason Gotlib4, Wolfgang R Sperr5,6, Karin Hartmann7,8, Lawrence B Schwartz9, Cem Akin10, Hans-Peter Horny11, Peter Valent5,6.   

Abstract

Mastocytosis are a group of hematologic neoplasms characterized by an accumulation of atypical mast cells in one or several organs/tissues, often accompanied by mast cell activation. Whereas in children the disease manifestations are mostly limited to the skin, in adults the disease is usually systemic (systemic mastocytosis; SM) and involves the bone marrow and/or other internal organs. Several variants of SM have been defined. Whereas most patients have indolent SM, some patients have advanced SM, which underlines the complexity of SM. In 2002, a European consortium of clinicians and scientists initiated a multidisciplinary, multi-national cooperative network, termed the 'European Competence Network on Mastocytosis' (ECNM), with the aim to improve diagnosis and therapy of patients with mastocytosis and other mast cell activation disorders. Since then, members of the ECNM have organized Annual Meetings in several European countries. The present article provides a summary of advances in the field presented during the 17th Annual ECNM meeting held in Salzburg in October 2019.

Entities:  

Keywords:  KIT; Mast cell activation; classification; mastocytosis; scoring; tyrosine-kinase inhibitors

Mesh:

Year:  2019        PMID: 31876203      PMCID: PMC7115828          DOI: 10.1080/10428194.2019.1703974

Source DB:  PubMed          Journal:  Leuk Lymphoma        ISSN: 1026-8022


  52 in total

1.  Long-term efficacy and safety of cladribine (2-CdA) in adult patients with mastocytosis.

Authors:  Stéphane Barete; Olivier Lortholary; Gandhi Damaj; Isabelle Hirsch; Marie Olivia Chandesris; Caroline Elie; Mohamed Hamidou; Isabelle Durieu; Felipe Suarez; Bernard Grosbois; Nicolas Limal; Emmanuel Gyan; Claire Larroche; Gérard Guillet; Jean Emmanuel Kahn; Philippe Casassus; Karima Amazzough; Hélène Coignard-Biehler; Sophie Georgin-Lavialle; Ludovic Lhermitte; Sylvie Fraitag; Danielle Canioni; Patrice Dubreuil; Olivier Hermine
Journal:  Blood       Date:  2015-05-22       Impact factor: 22.113

2.  Omalizumab prevents anaphylaxis and improves symptoms in systemic mastocytosis: Efficacy and safety observations.

Authors:  S Broesby-Olsen; H Vestergaard; C G Mortz; B Jensen; T Havelund; A P Hermann; F Siebenhaar; M B Møller; T K Kristensen; C Bindslev-Jensen
Journal:  Allergy       Date:  2017-07-27       Impact factor: 13.146

Review 3.  Proposed Diagnostic Algorithm for Patients with Suspected Mast Cell Activation Syndrome.

Authors:  Peter Valent; Cem Akin; Patrizia Bonadonna; Karin Hartmann; Knut Brockow; Marek Niedoszytko; Boguslaw Nedoszytko; Frank Siebenhaar; Wolfgang R Sperr; Joanna N G Oude Elberink; Joseph H Butterfield; Ivan Alvarez-Twose; Karl Sotlar; Andreas Reiter; Hanneke C Kluin-Nelemans; Olivier Hermine; Jason Gotlib; Sigurd Broesby-Olsen; Alberto Orfao; Hans-Peter Horny; Massimo Triggiani; Michel Arock; Lawrence B Schwartz; Dean D Metcalfe
Journal:  J Allergy Clin Immunol Pract       Date:  2019-02-05

4.  Progressive multifocal leukoencephalopathy in a patient with systemic mastocytosis treated with cladribine.

Authors:  Karl B Alstadhaug; Randi Fykse Halstensen; Francis Odeh
Journal:  J Clin Virol       Date:  2016-12-14       Impact factor: 3.168

5.  SRSF2-p95 hotspot mutation is highly associated with advanced forms of mastocytosis and mutations in epigenetic regulator genes.

Authors:  Katia Hanssens; Fabienne Brenet; Julie Agopian; Sophie Georgin-Lavialle; Gandhi Damaj; Laure Cabaret; Maria Olivia Chandesris; Paulo de Sepulveda; Olivier Hermine; Patrice Dubreuil; Erinn Soucie
Journal:  Haematologica       Date:  2014-01-03       Impact factor: 9.941

6.  Omalizumab Therapy for Mast Cell-Mediator Symptoms in Patients with ISM, CM, MMAS, and MCAS.

Authors:  Richard Lemal; Guillemette Fouquet; Louis Terriou; Mélanie Vaes; Cristina Bulai Livideanu; Laurent Frenzel; Stéphane Barete; Danielle Canioni; Ludovic Lhermitte; Julien Rossignol; Michel Arock; Patrice Dubreuil; Olivier Lortholary; Olivier Hermine
Journal:  J Allergy Clin Immunol Pract       Date:  2019-04-05

7.  CD44 is a RAS/STAT5-regulated invasion receptor that triggers disease expansion in advanced mastocytosis.

Authors:  Niklas Mueller; Daniel Wicklein; Gregor Eisenwort; Mohamad Jawhar; Daniela Berger; Gabriele Stefanzl; Georg Greiner; Alexandra Boehm; Christoph Kornauth; Leonhard Muellauer; Susanne Sehner; Gregor Hoermann; Wolfgang R Sperr; Philipp B Staber; Ulrich Jaeger; Johannes Zuber; Michel Arock; Udo Schumacher; Andreas Reiter; Peter Valent
Journal:  Blood       Date:  2018-07-17       Impact factor: 22.113

Review 8.  European Competence Network on Mastocytosis (ECNM): 10-year jubilee, update, and future perspectives.

Authors:  Peter Valent; Michel Arock; Patrizia Bonadonna; Knut Brockow; Sigurd Broesby-Olsen; Luis Escribano; Karoline V Gleixner; Clive Grattan; Emir Hadzijusufovic; Hans Hägglund; Olivier Hermine; Hans-Peter Horny; Hanneke C Kluin-Nelemans; Marcus Maurer; Marek Niedoszytko; Boguslaw Nedoszytko; Gunnar Nilsson; Hanneke N G Oude-Elberink; Alberto Orfao; Deepti Radia; Andreas Reiter; Frank Siebenhaar; Karl Sotlar; Wolfgang R Sperr; Massimo Triggiani; Jaap J VanDoormaal; Judit Várkonyi; Selim Yavuz; Karin Hartmann
Journal:  Wien Klin Wochenschr       Date:  2012-11-20       Impact factor: 1.704

9.  Identification of a leukemia-initiating stem cell in human mast cell leukemia.

Authors:  Gregor Eisenwort; Irina Sadovnik; Juliana Schwaab; Mohamad Jawhar; Alexandra Keller; Gabriele Stefanzl; Daniela Berger; Katharina Blatt; Gregor Hoermann; Martin Bilban; Michael Willmann; Christiana Winding; Wolfgang R Sperr; Michel Arock; Thomas Rülicke; Andreas Reiter; Peter Valent
Journal:  Leukemia       Date:  2019-04-05       Impact factor: 11.528

Review 10.  Ludwig Boltzmann Cluster Oncology (LBC ONC): first 10 years and future perspectives.

Authors:  Peter Valent; Emir Hadzijusufovic; Thomas Grunt; Heidrun Karlic; Barbara Peter; Harald Herrmann; Gregor Eisenwort; Gregor Hoermann; Axel Schulenburg; Michael Willmann; Rainer Hubmann; Medhat Shehata; Edgar Selzer; Karoline V Gleixner; Thomas Rülicke; Wolfgang R Sperr; Brigitte Marian; Michael Pfeilstöcker; Hubert Pehamberger; Felix Keil; Ulrich Jäger; Christoph Zielinski
Journal:  Wien Klin Wochenschr       Date:  2018-07-13       Impact factor: 1.704

View more
  5 in total

1.  Systemic mastocytosis with acute myeloid leukemia occurs from mutually exclusive clones expressing KITD816V and FLT3-ITD.

Authors:  Jose-Mario Capo-Chichi; Elizabeth Kagotho; Rakesh Nayyar; Davidson Zhao; Mark Minden; Hong Chang
Journal:  Leukemia       Date:  2020-10-26       Impact factor: 11.528

2.  CDK4/CDK6 Inhibitors Synergize with Midostaurin, Avapritinib, and Nintedanib in Inducing Growth Inhibition in KIT D816V+ Neoplastic Mast Cells.

Authors:  Mathias Schneeweiss-Gleixner; Yüksel Filik; Gabriele Stefanzl; Daniela Berger; Irina Sadovnik; Karin Bauer; Dubravka Smiljkovic; Gregor Eisenwort; Nadine Witzeneder; Georg Greiner; Gregor Hoermann; Ana-Iris Schiefer; Juliana Schwaab; Mohamad Jawhar; Andreas Reiter; Wolfgang R Sperr; Michel Arock; Peter Valent; Karoline V Gleixner
Journal:  Cancers (Basel)       Date:  2022-06-23       Impact factor: 6.575

Review 3.  Integration of in vitro allergy test results and ratio analysis for the diagnosis and treatment of allergic patients (INTEGRA).

Authors:  Mariona Pascal; Carmen Moreno; Ignacio Dávila; Ana I Tabar; Joan Bartra; Moisés Labrador; Olga Luengo
Journal:  Clin Transl Allergy       Date:  2021-08       Impact factor: 5.657

4.  Interrogating the molecular genetics of chronic myeloproliferative malignancies for personalized management in 2021.

Authors:  Tariq I Mughal; Bethan Psaila; Daniel J DeAngelo; Giuseppe Saglio; Richard A Van Etten; Jerald P Radich
Journal:  Haematologica       Date:  2021-07-01       Impact factor: 9.941

5.  How persons with systemic mastocytosis describe the time between symptom onset and receiving diagnosis.

Authors:  Kerstin Hamberg Levedahl; Annika Nilsson; Birgitta Johansson; Mariann Hedström
Journal:  Prim Health Care Res Dev       Date:  2022-09-07       Impact factor: 1.792

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.